SCHEDULE: Paradigm Capital Management Discloses Integra Lifesciences Stake

Paradigm Capital Management, Inc. has reported beneficial ownership of 5.2% of Integra Lifesciences Holdings Corp. common stock as of March 31, 2026.

Summary

• Paradigm Capital Management, Inc. has filed a Schedule 13G, indicating it beneficially owns 4,012,698 shares of Integra Lifesciences Holdings Corp. common stock.
• This ownership represents 5.2% of the class of securities.
• The filing date for this event is March 31, 2026.
• Paradigm Capital Management, Inc. has sole voting power and sole dispositive power over these shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports on an existing investment's status rather than new company performance or strategic shifts.

Positives

• Paradigm Capital Management, Inc. has acquired a significant stake (5.2%) in Integra Lifesciences Holdings Corp., suggesting confidence in the company's future prospects.
• The reporting person has sole voting and dispositive power, indicating clear control over their investment decisions regarding these shares.

Risks

• As a significant shareholder, Paradigm Capital Management, Inc.'s investment decisions could influence market perception and stock price volatility.
• The filing does not provide specific reasons for the acquisition, leaving potential strategic intentions open to interpretation.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Integra Lifesciences Holdings Corp. It solely reports on Paradigm Capital Management's ownership stake.

Industry Context

StockSavvy.ai notes that significant stake acquisitions reported via Schedule 13G filings often signal increased institutional interest or a shift in investment strategy within the medical technology sector, where Integra Lifesciences operates.

Stakeholder Impact

• Shareholders: The acquisition by a significant institutional investor may be viewed positively, potentially increasing demand for shares and influencing price. However, it also means a larger portion of the company is held by a single entity.
• Management: The increased institutional ownership may lead to closer scrutiny of company performance and strategic decisions.
• Creditors: No direct impact is indicated, as the filing pertains to equity ownership.

Next Steps

• Paradigm Capital Management, Inc. will continue to hold and manage its investment in Integra Lifesciences Holdings Corp. according to its investment strategy.
• Integra Lifesciences Holdings Corp. will continue its business operations as usual, subject to market conditions and its strategic plans.

Key Dates

Keywords

Integra Lifesciences Holdings Corp, Schedule 13G, Paradigm Capital Management, Beneficial Ownership, Common Stock, SEC Filing, Investment, Shareholder